MedPath

广东恒健制药有限公司

Ownership
-
Established
1994-02-23
Employees
-
Market Cap
-
Website
www.hengjian.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

135

NMPA:135

Drug Approvals

Cefprozil for Suspension

Product Name
头孢丙烯干混悬剂
Approval Number
国药准字H20254445
Approval Date
Jun 3, 2025
NMPA

Tadalafil Tablets

Product Name
他达拉非片
Approval Number
国药准字H20249849
Approval Date
Dec 25, 2024
NMPA

Tadalafil Tablets

Product Name
他达拉非片
Approval Number
国药准字H20249834
Approval Date
Dec 25, 2024
NMPA

Cefdinir Granules

Product Name
头孢地尼颗粒
Approval Number
国药准字H20244277
Approval Date
Jun 28, 2024
NMPA

Tobramycin Eye Drops

Product Name
妥布霉素滴眼液
Approval Number
国药准字H20198005
Approval Date
Jun 12, 2024
NMPA

Ranitidine Hydrochloride Capsules

Product Name
盐酸雷尼替丁胶囊
Approval Number
国药准字H44021173
Approval Date
May 14, 2024
NMPA

Sulfadiazine Silver Cream

Product Name
磺胺嘧啶银乳膏
Approval Number
国药准字H44020614
Approval Date
May 14, 2024
NMPA

Glycerine Enema

Product Name
开塞露(含甘油)
Approval Number
国药准字H44023815
Approval Date
May 14, 2024
NMPA

Naphazoline Hydrochloride Nasal Drops

Product Name
盐酸萘甲唑啉滴鼻液
Approval Number
国药准字H20198006
Approval Date
Apr 9, 2024
NMPA

Sulfacetamide Sodium Eye Drops

Product Name
磺胺醋酰钠滴眼液
Approval Number
国药准字H20198004
Approval Date
Mar 15, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 14
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.